Vazyme(SH:688105) 智通财经网·2026-02-26 11:50Core Viewpoint - The company reported its 2025 annual performance, showing stable revenue but a net loss, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved an operating revenue of 1.378 billion yuan, which is approximately flat compared to the same period last year [1] - The net profit attributable to the parent company was a loss of 16.97 million yuan, while the net profit after deducting non-recurring gains and losses was a loss of 79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company did not meet the performance assessment targets related to the 2023 restricted stock incentive plan, leading to a reversal of previously accrued share-based payment expenses at the end of the reporting period [1] Deferred Tax Assets - Based on a principle of prudence, the company reversed part of the previously recognized deferred tax assets, resulting in an increase in income tax expenses [1]